Core Capabilities:

Fed-Batch Process Development:

Industry-standard approach leveraging platform technologies to optimize cell growth and productivity. Ideal for monoclonal antibodies and recombinant proteins,offering a balance between performance and scalability.

Intensified Process Development:

Advanced upstream designs, such as high-density seed trains and media/feed optimization to reduce timelines,increase titers,and improve facility utilization Supports rapid scale-up and tech transfer.

Perfusion Process Development:

Continuous bioprocessing expertise for labile or complex molecules requiring steady-state conditions. Enables high productivity with consistent product quality-suited for next-gen biologics and high-demand therapies.

Advantages of Perfusion:

• Steady-state production for consistent product quality
• High volumetric productivity
• Improved control of critical quality attributes (CQAs)
• Ready for GMP implementation using ATF

Next Gen Perfusion Process Development:

A next-generation perfusion process leverages advanced bioprocessing technologies to enable high cell seeding densities and ultra-high culture densities 100 million cells/mL), resulting in significantly enhanced productivity, product quality, and manufacturing flexibility.

Advantages of Next Gen Perfusion:

• Faster achievement of the production phase
• Shorter culture duration
• Higher volumetric productivity (more product per liter per day)
• Better synchronization of the cell population